IN
INCY
HealthcareIncyte Corporation
Biotechnology
Total Trades
6
Unique Traders
2
Purchases / Sales
3/3
News Articles
5
Trading History
| Date | Politician | Asset | Action | Amount | Trade Price | 30D Price | 1M Return | Alpha | 1M Prediction |
|---|---|---|---|---|---|---|---|---|---|
Jan 29, 2026 |  Rohit KhannaD | Stock | Buy | $1,001 - $15,000 | $101.08 | $101.27 | +0.2% | +1.3% | |
May 19, 2025 | Rohit KhannaD | Stock | Buy | $1,001 - $15,000 | $63.81 | $68.27 | +7.0% | +6.6% | |
May 15, 2025 |  Rob BresnahanR | Stock | Sell | $1,001 - $15,000 | $62.76 | $67.75 | +8.0% | +6.8% | |
Feb 19, 2025 | Rohit KhannaD | Stock | Sell | $1,001 - $15,000 | $70.16 | $61.92 | -11.7% | -4.0% | |
Jan 17, 2025 | Rohit KhannaD | Stock | Buy | $1,001 - $15,000 | $71.93 | $70.42 | -2.1% | -4.1% | |
Dec 18, 2024 | Rohit KhannaD | Stock | Sell | $1,001 - $15,000 | $67.55 | $71.93 | +6.5% | +4.2% |
Recent News
Unveiling Incyte (INCY) Q4 Outlook: Wall Street Estimates for Key Metrics
Yahoo-Invalid Date
HC Wainwright & Co. Initiates Coverage On Incyte with Buy Rating, Announces Price Target of $135
Benzinga-Invalid Date
Royalty Pharma (RPRX) Earnings Expected to Grow: Should You Buy?
Yahoo-Invalid Date
A Glimpse Into The Expert Outlook On Incyte Through 8 Analysts
Benzinga-Invalid Date
TD Cowen Keeps Buy Rating on Incyte (INCY), Cites Roadmap to Triple Non-Jakafi Revenue by 2029
Yahoo-Invalid Date